在神经退行性疾病中,morpholine基化合物的治疗潜力:SAR洞察和分析
Suresh Kumar1, Poonam Bishnoi1, Naveen Chauhan1
1Department of Chemistry, Kurukshetra University, Kurukshetra, India.
Future medicinal chemistry
|June 9, 2025
概括
本综述探讨了通过优化其结构和特性来治疗神经退行性疾病的基于morpholine的化合物. 它强调了开发有效,选择性和更安全的候选药物的关键特征.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药物发现 药物发现 药物发现
背景情况:
- 神经退行性疾病涉及由于酶问题和细胞通信不良而导致的神经元损伤.
- 吗啡衍生物在调节诸如乙胆酶 (AChE),丁胆酶 (BuChE) 和单胺氧化酶 (MAO-A,MAO-B) 等关键酶方面表现有前途.
研究的目的:
- 审查基于结构的策略来设计作为抗神经退行性物质的形态素结合的异环环.
- 分析最近 (2019-2024) 在优化这些化合物的疗效,选择性和药物相似性的进展.
主要方法:
- 对形态素衍生物的基于结构的分析.
- 最近科学文献 (2019-2024) 的汇编和分析.
- 评估合成策略,结构-活性关系 (SAR) 和药理动力学特性.
主要成果:
- 确定了关键的分子特征,提高了morpholine衍生物的疗效,选择性和药物相似性.
- 总结了合成方法来创造多样化的形态杂物.
- 强调了药理动力学和in silico研究在优化化合物的作用.
结论:
- 摩尔福林结合的异循环为开发针对神经退行性疾病的新疗法提供了一个有前途的框架.
- 合理的药物设计整合SAR,合成和药理动力学对于推动这些药物的发展至关重要.
- 进一步的研究可能会导致下一代基于morpholine的药物,具有更好的治疗潜力和临床可翻译性.
更多相关视频
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.6K
07:32Analyzing Mitochondrial Transport and Morphology in Human Induced Pluripotent Stem Cell-Derived Neurons in Hereditary Spastic Paraplegia
Published on: February 9, 2020
7.9K
相关概念视频
Parkinson's Disease: Overview
723
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
723
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
